Agar, Nathalie Y. R.

Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data

Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., et al. (2018) · Neuro-Oncology

Barrier Structure and Function StudiesGlioma Diagnosis and Treatment

Cited by 746

Automatic 3D Nonlinear Registration of Mass Spectrometry Imaging and Magnetic Resonance Imaging Data

Abdelmoula, W. M., Regan, M. S., Lopez, B. G. C., Randall, E. C., Lawler, S., Mladek, A. C., Nowicki, M. O., Marin, B. M., Agar, J. N., Swanson, K. R., et al. (2019) · Analytical Chemistry

Mass Spectrometry Techniques and ApplicationsMedical Image Segmentation Techniques

Cited by 62

Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier

Kim, M., Ma, D. J., Calligaris, D., Zhang, S., Feathers, R. W., Vaubel, R. A., Meaux, I., Mladek, A. C., Parrish, K. E., Jin, F., et al. (2018) · Molecular Cancer Therapeutics

Glioma Diagnosis and TreatmentBarrier Structure and Function Studies

Cited by 39

A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma

Rendo, V., Lee, E. Q., Bossi, C., Khuu, N., Rudek, M. A., Pal, S., Azazmeh, N., Rashid, R., Lin, J.-R., Cusick, M., et al. (2025) · Science Translational Medicine

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 19

Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma

Vaubel, R. A., Zhang, W., Oh, J.-H., Mladek, A. C., Pasa, T. I., Gantchev, J. K., Waller, K. L., Baquer, G., Stopka, S. A., Regan, M. S., et al. (2025) · Clinical Cancer Research

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 2